New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

When you are the only teenager in your friend group who can’t wear earrings, that can be pretty disappointing. (Topical treatments are also tricky for scalp psoriasis patients since creams and ...

Psoriasis and dandruff can both trigger itching and flaky scalp skin. Psoriasis is a chronic autoimmune disorder that can cause thick patches of skin known as plaques on the scalp to become dry ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

It can also develop on other parts of your body, like your scalp or knees. It’s thought that about 3% of the population has psoriasis. Kids and teens can get psoriasis, but it happens mainly in ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...